MedTrace Logo

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

NCT07480733 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and preliminary efficacy of JS212, JS213, as well as JS212 in combination with JS213, toripalimab, and JS207.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

JS212 for Injection

administered by intravenous infusion on Day 1 of each 21-day cycle.

DRUG

JS213 for Injection

administered by intravenous infusion on Day 1 of each 21-day cycle.

DRUG

JS207 for Injection

administered by intravenous infusion on Day 1 of each 21-day cycle.

DRUG

Toripalimab

administered by intravenous infusion on Day 1 of each 21-day cycle.

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-23
Primary Completion
2027-11-30
Completion
2028-11-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07480733 on ClinicalTrials.gov